Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment of metastatic triple-negative breast cancer following a Phase Ib ORR readout for the combo at AACR on Monday.
At the American Association for Cancer Research meeting in Atlanta, Roche (SIX:ROG; OTCQX:RHHBY) reported preliminary Phase Ib data showing that first-line treatment with oral ipatasertib plus Tecentriq and paclitaxel/Abraxane nab-paclitaxel led to a confirmed objective response rate (ORR) of 73%. The responses were seen irrespective of tumor biomarker status, including PD-L1 status. Data were from 26 patients with locally advanced or metastatic TNBC who have not previously received chemotherapy in the advanced setting...